National patterns of cessation of prescription opioids among Medicare beneficiaries, 2013-2018.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
26 Aug 2022
26 Aug 2022
Historique:
entrez:
31
8
2022
pubmed:
1
9
2022
medline:
2
9
2022
Statut:
ppublish
Résumé
To understand the changes in opioid cessation surrounding the release of CDC guidelines and changes in state Medicaid coverage at the individual patient level. This study used a 20% national sample of Medicare beneficiaries between 2013 and 2018 with at least 90 days of consecutive opioid use in the first year of either of 2 study periods (2013-2015 or 2016-2018). Cessation of opioid use was assessed in year 3 of each period by generalized linear mixed models. Opioid cessation rates were higher in period 2 (11.2%) compared to period 1 (10.1%). Adjusted for beneficiary characteristics, those in period 2 had 1.07 times the odds of cessation (95% CI: 1.05-1.09) compared to those in period 1. Additionally, the increase in opioid cessation over time was larger in states with Medicaid expansion compared to those without. The increase in opioid cessation after 2016 suggests the potential effects of the CDC guidelines on opioid prescribing and underscores the need for further research on the relationship between opioid cessation and subsequent change in pain control, quality of life, and opioid toxicity.
Identifiants
pubmed: 36042655
doi: 10.1097/MD.0000000000029944
pii: 00005792-202208260-00074
pmc: PMC9410627
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29944Subventions
Organisme : NIDA NIH HHS
ID : R01 DA039192
Pays : United States
Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no financial, personal, or other potential conflicts of interest to disclose.
Références
Guy GP, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66:697–704.
Office of diversion control, drug & chemical evaluation section. Hydrocodone. Drug enforcement administration. 2014. Available at: https://www.deadiversion.usdoj.gov/drug_chem_info/hydrocodone.pdf [Access date February 5, 2021].
Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule. Fed Regist. 2014;79:49661–82.
Status of state action on the medicaid expansion decision. KFF. Published July 9, 2021. [Access date July 16, 2021]. https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/ .
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016. MMWR Recomm Rep. 2016;65.
Kuo Y-F, Raji MA, Liaw V, et al. Opioid prescriptions in older medicare beneficiaries after the 2014 federal rescheduling of hydrocodone products. J Am Geriatr Soc. 2018;66:945–53.
Liaw V, Kuo Y-F, Raji MA, et al. Opioid prescribing among adults with disabilities in the United States after the 2014 federal hydrocodone rescheduling regulation. Public Health Rep. 2019;135:114–23.
Champagne-Langabeer T, Madu R, Giri S, et al. Opioid prescribing patterns and overdose deaths in Texas. Subst Abuse. 2019;0:1–7.
U.S. Opioid dispensing rate maps | drug overdose | CDC injury center. Published December 7, 2020. [Access date February 10, 2021]. https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html .
CDC prescription drugs publications and resources public health law. Published February 22, 2019. [Access date February 25, 2021]. https://www.cdc.gov/phlp/publications/topic/prescription.html .
Nguyen AV, Ross E, Westra J, et al. Opioid utilization in geriatric patients after operation for degenerative spine disease. J Neurosurg Anesthesiol. 2021;33:315–22.
Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use following total knee and total hip arthroplasty. Pain. 2016;157:1259–65.
Ren M, Bryant BR, Harris AB, et al. Opioid use after adult spinal deformity surgery: patterns of cessation and associations with preoperative use. J Neurosurg Spine. 2020;33:490–5.
Clarke H, Soneji N, Ko DT, et al. Rates and risk factors for prolonged opioid use after major surgery: population based cohort study. BMJ. 2014;348:g1251.
Hills JM, Carlile CR, Archer KR, et al. Duration and dosage of opioids after spine surgery: implications on outcomes at 1 year. Spine. 2020;45:1081–8.
Carroll I, Barelka P, Wang CKM, et al. A pilot cohort study of the determinants of longitudinal opioid use after surgery. Anesth Analg. 2012;115:694–702.
Lall MP, Restrepo E. Predictors of weeks to opioid cessation after lumbar fusion: a prospective cohort study. Pain Manag Nurs Off J Am Soc Pain Manag Nurses. 2018;19:525–34.
Bohnert ASB, Guy GP, Losby JL. Opioid prescribing in the united states before and after the centers for disease control and prevention’s 2016 opioid guideline. Ann Intern Med. 2018;169:367–75.
Guy GP, Zhang K, Schieber LZ, et al. County-level opioid prescribing in the united states, 2015 and 2017. JAMA Intern Med. 2019;179:574–6.
Scherrer JF, Tucker J, Salas J, et al. Comparison of opioids prescribed for patients at risk for opioid misuse before and after publication of the centers for disease control and prevention’s opioid prescribing guidelines. JAMA Netw Open. 2020;3:e2027481.
Zhang VS, Olfson M, King M. Opioid and benzodiazepine coprescribing in the United States before and after US food and drug administration boxed warning. JAMA Psychiatry. 2019;76:1208–10.
Clemans-Cope L, Lynch V, Winiski E, et al. State variation in medicaid prescriptions for opioid use disorder from 2011 to 2018. Urban Institute. Available at: https://www.urban.org/research/publication/state-variation-medicaid-prescriptions-opioid-use-disorder-2011-2018 [Access date August 2, 2021].
Kuo Y-F, Raji MA, Goodwin JS. Association of disability with mortality from opioid overdose among US medicare adults. JAMA Netw Open. 2019;2:e1915638.
Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393:1760–72.
Kuo Y-F, Baillargeon J, Raji MA. Overdose deaths from nonprescribed prescription opioids, heroin, and other synthetic opioids in medicare beneficiaries. J Subst Abuse Treat. 2021;124:108282.
Seth P, Scholl L, Rudd RA, et al. Overdose deaths involving opioids, cocaine, and psychostimulants United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67:349–58.